Illumina (ILMN) Stock Forecast & Price Target

$136.48 -7.74 (-5.37%)

As of 01/14/2025 04:00 PM Eastern

Illumina - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 20 Analyst Ratings

Sell
0

Hold
8

Buy
12

Based on 20 Wall Street analysts who have issued ratings for Illumina in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 20 analysts, 8 have given a hold rating, 10 have given a buy rating, and 2 have given a strong buy rating for ILMN.

Consensus Price Target

$165.63
21.36% Upside

According to the 20 analysts' twelve-month price targets for Illumina, the average price target is $165.63. The highest price target for ILMN is $254.00, while the lowest price target for ILMN is $115.00. The average price target represents a forecasted upside of 21.36% from the current price of $136.48.

Get the Latest News and Ratings for ILMN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Illumina and its competitors.

ILMN Analyst Ratings Over Time

Type	Current Forecast 1/16/24 to 1/15/25	1 Month Ago 12/17/23 to 12/16/24	3 Months Ago 10/18/23 to 10/17/24	1 Year Ago 1/16/23 to 1/16/24
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	10 Buy rating(s)	10 Buy rating(s)	13 Buy rating(s)	9 Buy rating(s)
Hold	8 Hold rating(s)	8 Hold rating(s)	8 Hold rating(s)	10 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$165.63	$165.95	$155.50	$171.86
Forecasted Upside	21.36% Upside	14.92% Upside	8.35% Upside	27.17% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

ILMN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ILMN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Illumina Stock vs. The Competition

Type	Illumina	Medical Companies	S&P 500
Consensus Rating Score	2.70	2.82	2.52
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	21.36% Upside	24,950.25% Upside	14.85% Upside
News Sentiment Rating	Neutral News See Recent ILMN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
1/13/2025	Morgan Stanley 3 of 5 stars	Tejas Savant Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$156.00 ➝ $150.00	+4.30%
12/11/2024	Citigroup 3 of 5 stars	P. Donnelly Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$190.00 ➝ $165.00	+11.09%
11/12/2024	Stephens 4 of 5 stars		Boost Target	Overweight ➝ Overweight	$170.00 ➝ $184.00	+21.45%
11/11/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$195.00 ➝ $185.00	+22.44%
11/6/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$124.00 ➝ $139.00	-10.30%
11/5/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Brennan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$166.00 ➝ $177.00	+15.02%
Get the Latest News and Ratings for ILMN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.
11/5/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$133.00 ➝ $145.00	-4.89%
11/5/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$252.00 ➝ $254.00	+68.04%
11/5/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$125.00 ➝ $140.00	-7.76%
11/5/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Sergott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$135.00 ➝ $145.00	-3.65%
11/5/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$130.00 ➝ $145.00	-5.53%
10/17/2024	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Gupta Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy	$180.00	+25.42%
10/17/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$160.00 ➝ $200.00	+38.91%
10/17/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$180.00	+25.10%
8/28/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Hellweg Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$150.00	+14.59%
8/16/2024	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Nakagiri Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/16/2024	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$120.00 ➝ $154.00	+19.57%
8/15/2024	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Sector Outperform ➝ Sector Outperform	$176.00 ➝ $164.00	+27.33%
6/11/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$195.00 ➝ $175.00	+59.35%
6/3/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$115.00	+10.28%
3/20/2024	OTR Global Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Positive ➝ Mixed
12/15/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underperform ➝ Market Perform
12/14/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$155.00	+22.37%
12/13/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$175.00	+48.76%
12/12/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underperform	$140.00 ➝ $100.00	-14.99%
10/12/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$200.00	+49.91%
8/10/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$225.00 ➝ $200.00	+8.41%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 01:51 AM ET.

Should I Buy Illumina Stock? ILMN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, January 10, 2025. Please send any questions or comments about these Illumina pros and cons to contact@marketbeat.com.

Illumina
Bull Case

Here are some ways that investors could benefit from investing in Illumina, Inc.:

Illumina, Inc. recently reported earnings of $1.14 per share, exceeding the consensus estimate of $0.88 by $0.26, indicating strong financial performance.
The company has a market capitalization of approximately $22.82 billion, reflecting its significant presence in the life sciences sector and potential for growth.
Illumina's stock is currently trading at $143.87, which may present a buying opportunity for investors looking to enter at a lower price point compared to its 52-week high of $156.66.
Institutional investors hold 89.42% of Illumina's stock, suggesting strong confidence from major financial entities in the company's future prospects.
The company operates in a growing field of genetic and genomic analysis, which is increasingly important in healthcare, potentially leading to future revenue growth.

Illumina
Bear Case

Investors should be bearish about investing in Illumina, Inc. for these reasons:

Illumina reported a negative net margin of 36.10%, indicating that the company is currently spending more than it earns, which could be a concern for profitability.
The company's revenue decreased by 3.5% year-over-year, suggesting potential challenges in maintaining sales growth in a competitive market.
Illumina's price-to-earnings (P/E) ratio is -14.70, which indicates that the company is not currently profitable, making it a riskier investment.
Recent trading activity shows volatility, with the stock experiencing fluctuations, which may deter risk-averse investors.
With a debt-to-equity ratio of 0.94, the company has a relatively high level of debt compared to its equity, which could pose risks if market conditions worsen.

ILMN Forecast - Frequently Asked Questions

: According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Illumina is $165.63, with a high forecast of $254.00 and a low forecast of $115.00.
: 20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last twelve months. There are currently 8 hold ratings, 10 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ILMN shares.
: According to analysts, Illumina's stock has a predicted upside of 21.36% based on their 12-month stock forecasts.
: Over the previous 90 days, Illumina's stock had 2 upgrades and 1 downgrade by analysts.
: Illumina has been rated by research analysts at Barclays, Canaccord Genuity Group, Citigroup, Hsbc Global Res, HSBC, JPMorgan Chase & Co., Leerink Partners, Morgan Stanley, Piper Sandler, Robert W. Baird, Royal Bank of Canada, Stephens, TD Cowen, and UBS Group in the past 90 days.
: Analysts like Illumina less than other "medical" companies. The consensus rating score for Illumina is 2.70 while the average consensus rating score for "medical" companies is 2.82. Learn more on how ILMN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This page (NASDAQ:ILMN) was last updated on 1/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Illumina (ILMN) Stock Forecast & Price Target